2021年V1版《NCCN非小细胞肺癌临床诊治指南》更新解读  

Interpretation of updated NCCN guidelines for non-small cell lung cancer(version 1.2021)

作　　者：张家豪 张亚杰[1] 王洁[2] 李鹤成[1] ZHANG Jiahao;ZHANG Yajie;WANG Jie;LI Hecheng(Department of Thoracic Surgery,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,200025,P.R.China;Medical Oncology Department,Cancer Hospital Chinese Academy of Medical Sciences,Beijing,100021,P.R.China)

机构地区：[1]上海交通大学医学院附属瑞金医院胸外科,上海200025 [2]中国医学科学院肿瘤医院肿瘤内科,北京100021

出　　处：《中国胸心血管外科临床杂志》2021年第3期271-277,共7页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：国家自然科学基金项目(81871882,81902951);上海市卫生计生系统优秀学科带头人培养计划(2017BR055);上海市教育委员会高峰高原学科建设计划(20172005)。

摘　　要：美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)根据新的临床证据,更新发布的《NCCN非小细胞肺癌临床诊治指南》已成为全球临床医师遵循和认可的临床诊治参考。2020年11月25日,最新的2021年V1版《NCCN非小细胞肺癌临床诊治指南》(下文简称为《指南》)发布。相比2020年第8版《指南》有了众多更新,集中在靶向和免疫治疗进展。本文将对该版《指南》更新内容进行解读。Based on new clinical evidence,the National Comprehensive Cancer Network(NCCN)annually updates and releases the"NCCN Guidelines for the Clinical Diagnosis and Treatment of Non-Small Cell Lung Cancer"which has become the reference for clinical diagnosis and treatment approved and complied by clinicians worldwide.On November 25,2020,the latest 2021 V1 version of"NCCN Clinical Diagnosis and Treatment Guidelines for Non-Small Cell Lung Cancer"(hereinafter referred to as"Guidelines")was released.Compared with the 8 th edition of the"Guidelines"in2020,many updates focused on the progress of targeted and immunotherapy.This article will provide the interpretations of the updated therapy content of this edition of the guidelines.

关 键 词：非小细胞肺癌 NCCN指南 2021年V1版更新 指南解读 

分 类 号：R734.2[医药卫生—肿瘤]